Clinical trials: MDD
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Major Depressive Disorder (MDD)
Preventing Relapse After Successful Electroconvulsive Therapy for Depression
The present project is designed to study two promising relapse prevention strategies in an RCT. This will be the first project worldwide to study the effects of a personalized ECT treatment algorithm in the continuation phase of…
- Trial name
- PRASED (NCT06751875)
- Testing
- Lithium
- Where
- Belgium
- Volunteers
- 96 people
- Sponsor
- Universiteit Antwerpen
MDD
The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)
The MOOD study will evaluate the safety and efficacy of a noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation (eCOT-NS) treatment for Major Depressive Disorder (Relivion®DP).
- Trial name
- MDD (NCT04279522)
- Testing
- Relivion®DP- Active
- Where
- 13 sites in United States, Israel
- Volunteers
- 124 people
- Sponsor
- Neurolief Ltd.
Major Depressive Disorder (MDD), History of Childhood Sexual Abuse (CSA)
An Investigation of Early Life Stress and Depression
The purpose of this study is to investigate brain pathways within adult females (with a history of CSA that occurred between the ages of 5-14) with and without a current diagnosis of major depressive disorder (MDD).
- Trial name
- NCT01701258
- Testing
- Amisulpride
- Where
- 2 sites in United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Major Depressive Disorder, MDD
Mechanism of Action of tACS for the Treatment of MDD
The purpose of this research study is to use a specific type of non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) to determine its effects on brain activity (measured with EEG) and mood…
- Trial name
- GLADIATOR2 (NCT03994081)
- Testing
- tACS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
MDD
Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
This an open label study using a FDA-cleared TMS stimulation protocols which will be used to treat patients who have responded or remitted from depression using acute clinical TMS therapy at the University of Missouri-Columbia…
- Trial name
- NCT04076644
- Testing
- TMS treatment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Missouri-Columbia
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111565
- Testing
- Escitalopram, Aripiprazole
- Where
- 53 sites in United States, Canada and 9 more
- Volunteers
- 137 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111539
- Testing
- Escitalopram, Aripiprazole, Blinded capsule
- Where
- 62 sites in United States, Estonia and 7 more
- Volunteers
- 211 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, MDD
Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder
The primary purpose of this study is to test the safety and feasibility of virtual reality (VR) technology in the use of behavioral activation (BA) as a treatment for major depressive disorder (MDD).
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT04268316
- Testing
- Virtual Reality Behavioral Activation, Behavioral Activation in real-life
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
PTSD, MDD
Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression
This pilot study aims to test the safety, feasibility, and initial efficacy of combined 10 week treatment of prolonged exposure (PE) and Pramipexole in patients with comorbid posttraumatic stress disorder (PTSD) and depression…
- Trial name
- NCT03765138
- Testing
- PE/Pramipexole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
MDD
Effect of Bupropion on Seizure Threshold in Depressed Patients
The purpose of the study is to examine the effect of bupropion on seizure threshold and duration in depressed patients receiving right unilateral ultra-brief electroconvulsive therapy (ECT).
- Trial name
- NCT03126682
- Testing
- Wellbutrin SR 300Mg Extended-Release Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Major Depressive Disorder (MDD)
Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression
This feasibility study investigates effects of EEG-based low frequency, low emission magnetic cortical stimulation in comparison to a sham treatment in subjects with moderate to severe depressive disorder.
- Trial name
- NCT01683019
- Testing
- NeoSync EEG Synchronization Therapy
- Where
- 2 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder, MDD
Transcranial Alternating Current Stimulation for Major Depressive Disorder
Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on patients with Major Depressive Disorder (MDD).
- Trial name
- MDD (NCT02339285)
- Testing
- tACS (alpha), tACS (gamma)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder (MDD)
The Effects of Dopamine on Reward Processing
The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing.
- Trial name
- NCT01253421
- Testing
- amisulpride
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Major Depressive Disorder (MDD)
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
The purpose of this study is to assess if LY2216684 (flexible dose of 12 to 18 milligrams [mg] or fixed dose of 6 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with Major Depressive…
- Trial name
- NCT01187407
- Testing
- LY2216684, SSRI
- Where
- 54 sites in United States, Croatia and 5 more
- Volunteers
- 1,480 people
- Sponsor
- Eli Lilly and Company
MDD, Citalopram
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
Primarily, this study seeks to evaluate whether citalopram treatment is associated with an increase in the Glutamine (Gln)/Glutamate (Glu) ratio in the anterior cingulate cortex (ACC) from baseline to day 3 of treatment.
- Conditions
- MDD, Citalopram, Major Depressive Disorder
- Trial name
- NCT01557946
- Testing
- citalopram
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mclean Hospital
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.